P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

Authors :: Silvennoinen, Raija
Partanen, Anu
Waage, Anders
Pečeliūnas, Valdas
Schjesvold, Fredrik
Anttila, Pekka
Uttervall, Katarina
Säily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukas, Einar
Sankelo, Marja
Szatkowski, Damian
Hansson, Markus
Marttila, Anu
Axelsson, Per
Svensson, Ronald
Lauri, Birgitta
Mikkola, Maija
Karlsson, Conny
Source :: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p
Publication Year :: 2023

Full Text Access

Tools